CBC Group, in collaboration with Mubadala Investment Company, has finalized the acquisition of UCB's neurology and allergy business in China for $680m. This acquisition will establish NeuroGen Pharma, focusing on neuro healthcare innovation, to address evolving treatment needs in the country.